Do you avoid using tafasitamab in germinal center subtype diffuse large B-cell lymphoma?

I don’t! I think the rationale behind the question is that tafasitamab has to be given with lenalidomide which has been shown to be more efficacious in non-GCB DLBCL. The rationale of combining lenalidomide with tafasitamab has more to do with expansion of NK cells to augment tafasitamab-mediated antibody dependent cytotoxicity (ADCC) as tafasitamab is engineered to optimize ADCC, also lenalidomide modulates CD19 expression on lymphoma cells. There is no data to suggest that GCB patients respond...